# Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)

> **NCT01225146** · PHASE1 · TERMINATED · sponsor: **David M. Brown, M.D.** · enrollment: 8 (actual)

## Conditions studied

- Ischemia
- Retinal Vein Occlusion
- Pathologic Processes
- Retinal Diseases
- Eye Diseases

## Interventions

- **DRUG:** ranibizumab

## Key facts

- **NCT ID:** NCT01225146
- **Lead sponsor:** David M. Brown, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The collaborator, Genentech, stopped supplying the study drug to the site.
- **Last updated:** 2017-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01225146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01225146, "Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01225146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*